Home
/
Spyre Therapeutics, Inc.
/
Financials
/
Quarterly
Spyre Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Spyre Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2024
$0
Nov 18, 2024
Q2
2024
Jun 30, 2024
$0
Nov 18, 2024
Q1
2024
Mar 31, 2024
$0
Nov 18, 2024
Q3
2024
Sep 30, 2023
$0
Nov 18, 2024
Q2
2024
Jun 30, 2023
$688.0K
Nov 18, 2024
Q1
2024
Mar 31, 2023
$198.0K
Nov 18, 2024
Q3
2023
Sep 30, 2022
$174.0K
Nov 9, 2023
Q2
2023
Jun 30, 2022
$625.0K
Aug 11, 2023
Q1
2023
Mar 31, 2022
$1.36M
May 11, 2023
Q3
2022
Sep 30, 2021
$1.40M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$13.70M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$0
May 5, 2022
Q3
2019
Sep 30, 2019
$0
Nov 6, 2019
Q2
2019
Jun 30, 2019
$0
Aug 6, 2019
Q1
2019
Mar 31, 2019
$0
May 7, 2019
Q3
2019
Sep 30, 2018
$0
Nov 6, 2019
Q2
2019
Jun 30, 2018
$2.38M
Aug 6, 2019
Q1
2019
Mar 31, 2018
$1.51M
May 7, 2019
Q3
2018
Sep 30, 2017
$1.26M
Nov 8, 2018
Q2
2018
Jun 30, 2017
$1.48M
Aug 9, 2018
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($11.18M)
Nov 4, 2025
Q3
2025
Jun 30, 2025
($36.72M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($36.72M)
Aug 5, 2025
Q2
2025
Mar 31, 2025
($44.77M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($44.77M)
May 8, 2025
Q3
2025
Mar 31, 2025
($44.77M)
Nov 4, 2025
Q3
2025
Sep 30, 2024
($69.03M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($38.84M)
Aug 5, 2025
Q3
2025
Jun 30, 2024
($38.84M)
Nov 4, 2025
Q2
2025
Mar 31, 2024
($43.86M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($43.86M)
May 8, 2025
Q3
2025
Mar 31, 2024
($43.86M)
Nov 4, 2025
Q3
2024
Sep 30, 2023
($40.11M)
Nov 18, 2024
Q3
2024
Jun 30, 2023
($217.08M)
Nov 18, 2024
Q2
2024
Jun 30, 2023
($217.08M)
Nov 18, 2024
Q1
2024
Mar 31, 2023
($18.42M)
Nov 18, 2024
Q3
2024
Mar 31, 2023
($18.42M)
Nov 18, 2024
Q2
2024
Mar 31, 2023
($18.42M)
Nov 18, 2024
Q3
2023
Sep 30, 2022
($18.23M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($22.32M)
Aug 11, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($56.89M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($41.94M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($53.57M)
May 8, 2025
Q3
2025
Sep 30, 2024
($55.39M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($44.15M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($47.77M)
May 8, 2025
Q3
2024
Sep 30, 2023
($18.34M)
Nov 18, 2024
Q2
2024
Jun 30, 2023
($159.25M)
Nov 18, 2024
Q1
2024
Mar 31, 2023
($18.81M)
Nov 18, 2024
Q3
2023
Sep 30, 2022
($18.76M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($22.42M)
Aug 11, 2023
Q1
2023
Mar 31, 2022
($24.44M)
May 11, 2023
Q3
2022
Sep 30, 2021
($20.29M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($6.71M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($18.21M)
May 5, 2022
Q3
2021
Sep 30, 2020
($18.12M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($21.56M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($19.02M)
May 10, 2021
Q3
2020
Sep 30, 2019
($22.15M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($18.62M)
Aug 10, 2020